Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00286637 · ClinicalTrials.gov registry record

Novel Glaucoma Diagnostics

A clinical trial of Glaucoma and Macular Disease, sponsored by Wills Eye.

Recruiting
Registry status
5,000
Enrollment target
1
Study location

NCT00286637: Recruiting study of Glaucoma and Macular Disease, sponsored by Wills Eye.

NCT00286637 is a study of Glaucoma and Macular Disease that is actively recruiting participants, run by Wills Eye. The registered enrollment target is 5,000 participants, above the 856-participant average among 92 other Glaucoma trials with a reported enrollment target (484% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00286637, a study of Glaucoma and Macular Disease, is actively recruiting participants, sponsored by Wills Eye.

RECRUITING
Registry status
5,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Primary Outcome

The purpose of this research is to Participants who show evidence of glaucoma progression are classified as "progressors." Participants who show evidence of glaucoma progression are classified as "progressors."

Conditions Studied

Study Locations (1)

Pennsylvania

  • Wills Eye Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2000-08-01
Est. Completion 2029-07-31
Wills Eye

59 total trials

What NCT00286637 shows while recruiting

NCT00286637 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 856-participant average among 92 other Glaucoma trials with a reported enrollment target (484% higher).

The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 0 interventions.

NCT00286637 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00286637 about?

NCT00286637 is a clinical study titled "Novel Glaucoma Diagnostics". The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measu...

What is the current status of trial NCT00286637?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2000-08-01. Estimated completion is 2029-07-31.

What conditions does trial NCT00286637 study?

This clinical trial studies the following conditions: Glaucoma, Macular Disease.

Who is sponsoring clinical trial NCT00286637?

This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00286637 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00286637's enrollment target sits among peer trials

5,000 2nd of 92 the highest of 92 other Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

  • NCT00736749 · 5,000 participants

    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  • NCT00900198 · 5,000 participants

    Collection of Tissue Samples for Cancer Research

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00286637, the US trial registry maintained by the National Library of Medicine. NCT00286637 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.